These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12409059)

  • 1. Tamoxifen for primary breast cancer prevention in BRCA heterozygotes.
    Robson M
    Eur J Cancer; 2002 Nov; 38 Suppl 6():S18-9. PubMed ID: 12409059
    [No Abstract]   [Full Text] [Related]  

  • 2. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.
    Peshkin BN; Isaacs C; Finch C; Kent S; Schwartz MD
    J Clin Oncol; 2003 Dec; 21(23):4322-8. PubMed ID: 14645421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.
    King MC; Wieand S; Hale K; Lee M; Walsh T; Owens K; Tait J; Ford L; Dunn BK; Costantino J; Wickerham L; Wolmark N; Fisher B;
    JAMA; 2001 Nov; 286(18):2251-6. PubMed ID: 11710890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Tamoxifen may be an effective treatment for BRCA1-related breast cancer irrespective of estrogen receptor status.
    Cappelletti V; Veneroni S; Coradini D; Oriana S; Tomasic G; Younes M; Daidone MG
    J Natl Cancer Inst; 2003 Apr; 95(8):629-30. PubMed ID: 12697859
    [No Abstract]   [Full Text] [Related]  

  • 5. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.
    Schrag D; Kuntz KM; Garber JE; Weeks JC
    JAMA; 2000 Feb; 283(5):617-24. PubMed ID: 10665701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of ovarian ablation in the management of breast cancer.
    Wirk B
    Breast J; 2005; 11(6):416-24. PubMed ID: 16297086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoprevention of breast cancer.
    Osborne MP
    Surg Clin North Am; 1999 Oct; 79(5):1207-21. PubMed ID: 10572559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen may be an effective adjuvant treatment for BRCA1-related breast cancer irrespective of estrogen receptor status.
    Foulkes WD; Goffin J; Brunet JS; Bégin LR; Wong N; Chappuis PO
    J Natl Cancer Inst; 2002 Oct; 94(19):1504-6. PubMed ID: 12359859
    [No Abstract]   [Full Text] [Related]  

  • 9. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
    Metcalfe KA; Birenbaum-Carmeli D; Lubinski J; Gronwald J; Lynch H; Moller P; Ghadirian P; Foulkes WD; Klijn J; Friedman E; Kim-Sing C; Ainsworth P; Rosen B; Domchek S; Wagner T; Tung N; Manoukian S; Couch F; Sun P; Narod SA;
    Int J Cancer; 2008 May; 122(9):2017-22. PubMed ID: 18196574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations.
    Duffy SW; Nixon RM
    Br J Cancer; 2002 Jan; 86(2):218-21. PubMed ID: 11870509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?
    Phillips KA; Lindeman GJ
    Future Oncol; 2014 Mar; 10(4):499-502. PubMed ID: 24754577
    [No Abstract]   [Full Text] [Related]  

  • 12. [Are the hereditary forms of BRCA1 and BRCA2 breast cancer sensitive to estrogens?].
    Pujol P; This P; Noruzinia M; Stoppa-Lyonnet D; Maudelonde T
    Bull Cancer; 2004; 91(7-8):583-91. PubMed ID: 15381448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention and management of hereditary breast cancer.
    Narod SA; Offit K
    J Clin Oncol; 2005 Mar; 23(8):1656-63. PubMed ID: 15755973
    [No Abstract]   [Full Text] [Related]  

  • 14. Should you be taking tamoxifen?
    Johns Hopkins Med Lett Health After 50; 2001 Jun; 13(4):4-5. PubMed ID: 11439691
    [No Abstract]   [Full Text] [Related]  

  • 15. BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial.
    Kote-Jarai Z; Powles TJ; Mitchell G; Tidy A; Ashley S; Easton D; Assersohn L; Sodha N; Salter J; Gusterson B; Dowsett M; Eeles R
    Cancer Lett; 2007 Mar; 247(2):259-65. PubMed ID: 16777318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers.
    Osin P; Crook T; Powles T; Peto J; Gusterson B
    Lancet; 1998 May; 351(9114):1487. PubMed ID: 9605807
    [No Abstract]   [Full Text] [Related]  

  • 17. Compliance with tamoxifen in women with breast cancer and a BRCA1 or BRCA2 mutation.
    Narod SA
    J Clin Oncol; 2010 Nov; 28(33):e698-9; author reply e700. PubMed ID: 20921464
    [No Abstract]   [Full Text] [Related]  

  • 18. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.
    Gronwald J; Tung N; Foulkes WD; Offit K; Gershoni R; Daly M; Kim-Sing C; Olsson H; Ainsworth P; Eisen A; Saal H; Friedman E; Olopade O; Osborne M; Weitzel J; Lynch H; Ghadirian P; Lubinski J; Sun P; Narod SA;
    Int J Cancer; 2006 May; 118(9):2281-4. PubMed ID: 16331614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choices--and uncertainties--for women with BRCA mutations.
    Couzin J
    Science; 2003 Oct; 302(5645):592. PubMed ID: 14576419
    [No Abstract]   [Full Text] [Related]  

  • 20. Cross-issue synthesis: potential application to breast cancer, tamoxifen and genetic susceptibility.
    Nixon RM; Duffy SW
    J Cancer Epidemiol Prev; 2002; 7(4):205-12. PubMed ID: 12846491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.